Recent strategies and approaches for the development of molecularly targeted nanomedicine

Molecularly targeted nanomedicine has emerged as a transformative approach in modern drug delivery by integrating nanotechnology with molecular biology to achieve site-specific therapeutic action. Conventional pharmacotherapy often suffers from poor selectivity, systemic toxicity, limited bioavailability, and off-target effects, particularly in the treatment of complex diseases such as cancer, inflammatory disorders, and neurodegenerative conditions. Advances in the understanding of disease-specific molecular targets and pathological microenvironments have driven the development of nanocarriers capable of precise targeting and controlled drug release. This chapter provides a comprehensive overview of recent strategies and approaches employed in the design of molecularly targeted nanomedicines. It discusses fundamental principles of nanocarrier design, physicochemical properties influencing biological performance, and the mechanisms of passive and active targeting. Various classes of nanocarriers, including lipid-based, polymeric, inorganic, hybrid, and biomimetic systems, are critically examined with respect to their targeting potential. Additionally, the chapter highlights the role of targeting ligands, stimuli-responsive systems, and tumor microenvironment-specific strategies in enhancing therapeutic efficacy while minimizing adverse effects. Current challenges, translational barriers, and future perspectives are also addressed, emphasizing the potential of molecularly targeted nanomedicine to advance precision therapy and improve clinical outcomes.